Market access
How do you prove the lifetime benefits of a potentially life-altering one-off therapy through...
In previous work, we have shown that outcomes-based reimbursement (OBR), whereby payments to...
In previous work, we have shown that outcomes-based reimbursement (OBR), whereby payments to...
Outcomes-based managed entry agreements (MEAs) can enable patient access to promising high cost...
The HE&MA function of the CGT Catapult engaged with an ATMP developer to identify the US...
A key challenge for the commercial viability of ATMPs is achieving both a high price and...
Understanding how price, revenue and profit margins can be maximised is key to any commercial...
In response to the lack of sufficient information on market access processes for cell and gene...